BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 29877275)

  • 1. Recombinant Thrombomodulin Used to Successfully Treat Cronkhite-Canada Syndrome with Disseminated Intravascular Coagulation due to Sepsis in a Compromised Patient.
    Morino K; Honma Y; Kumei S; Watanabe T; Kume K; Yoshikawa I; Harada M
    Intern Med; 2018 Nov; 57(21):3079-3085. PubMed ID: 29877275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective comparative study of recombinant human thrombomodulin and gabexate mesilate in sepsis-induced disseminated intravascular coagulation patients.
    Takazono T; Nakamura S; Imamura Y; Yoshioka S; Miyazaki T; Izumikawa K; Sawai T; Matsuo N; Yanagihara K; Suyama N; Kohno S
    J Infect Chemother; 2014 Aug; 20(8):484-8. PubMed ID: 24855912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation.
    Vincent JL; Ramesh MK; Ernest D; LaRosa SP; Pachl J; Aikawa N; Hoste E; Levy H; Hirman J; Levi M; Daga M; Kutsogiannis DJ; Crowther M; Bernard GR; Devriendt J; Puigserver JV; Blanzaco DU; Esmon CT; Parrillo JE; Guzzi L; Henderson SJ; Pothirat C; Mehta P; Fareed J; Talwar D; Tsuruta K; Gorelick KJ; Osawa Y; Kaul I
    Crit Care Med; 2013 Sep; 41(9):2069-79. PubMed ID: 23979365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter clinical experience with recombinant soluble thrombomodulin for disseminated intravascular coagulation associated with severe acute cholecystitis.
    Ogura T; Eguchi T; Amano M; Sano T; Nishioka N; Miyano A; Tsujimae M; Tanimura H; Yamada T; Terashima Y; Okada A; Higuchi K
    Thromb Res; 2019 Apr; 176():74-78. PubMed ID: 30780007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TAFRO Syndrome with Disseminated Intravascular Coagulation Successfully Treated with Tocilizumab and Recombinant Thrombomodulin.
    Takayama Y; Kubota T; Ogino Y; Ohnishi H; Togitani K; Yokoyama A
    Intern Med; 2018 May; 57(9):1291-1296. PubMed ID: 29279488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human soluble thrombomodulin and mortality in sepsis-induced disseminated intravascular coagulation. A multicentre retrospective study.
    Hayakawa M; Yamakawa K; Saito S; Uchino S; Kudo D; Iizuka Y; Sanui M; Takimoto K; Mayumi T; Ono K;
    Thromb Haemost; 2016 Jun; 115(6):1157-66. PubMed ID: 26939575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors Determining the Efficacy of Recombinant Human Thrombomodulin in the Treatment of Sepsis-Induced Disseminated Intravascular Coagulation.
    Kotake K; Hongo T; Tahira A; Niimi N; Haisa I; Kawakami Y
    Biol Pharm Bull; 2021 May; 44(5):605-610. PubMed ID: 33612566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant soluble thrombomodulin as an adjunctive treatment for sepsis and disseminated intravascular coagulation: relatively safe and possibly effective.
    Fink MP
    Crit Care Med; 2013 Sep; 41(9):2221-3. PubMed ID: 23979366
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of Recombinant Human Soluble Thrombomodulin on Coagulation-Related Variables in Patients With Sepsis-Induced Disseminated Intravascular Coagulation: A Retrospective Observational Study.
    Mitaka C; Kawagoe I; Satoh D; Hayashida M
    Clin Appl Thromb Hemost; 2021; 27():10760296211050356. PubMed ID: 34859680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of recombinant human thrombomodulin and gabexate mesylate for treatment of disseminated intravascular coagulation (DIC) with sepsis following emergent gastrointestinal surgery: a retrospective study.
    Akahoshi T; Sugimori H; Kaku N; Tokuda K; Nagata T; Noda E; Morita M; Hashizume M; Maehara Y
    Eur J Trauma Emerg Surg; 2015 Oct; 41(5):531-8. PubMed ID: 26038004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adequate application of recombinant thrombomodulin for sepsis-associated disseminated intravascular coagulation.
    Iba T
    Crit Care; 2015 May; 19(1):233. PubMed ID: 26002185
    [No Abstract]   [Full Text] [Related]  

  • 12. Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis.
    Yoshimura J; Yamakawa K; Ogura H; Umemura Y; Takahashi H; Morikawa M; Inoue Y; Fujimi S; Tanaka H; Hamasaki T; Shimazu T
    Crit Care; 2015 Mar; 19(1):78. PubMed ID: 25883031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of sepsis-induced disseminated intravascular coagulation in a patient with idiopathic thrombocytopenic purpura using recombinant human soluble thrombomodulin.
    Koga T; Inoue D; Okada A; Aramaki T; Yamasaki S; Nakashima M; Kawakami A; Eguchi K
    Rheumatol Int; 2011 Dec; 31(12):1657-9. PubMed ID: 21240494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsis-induced disseminated intravascular coagulation - A meta-analysis.
    Kato H; Hagihara M; Asai N; Umemura T; Hirai J; Mori N; Yamagishi Y; Iwamoto T; Mikamo H
    Thromb Res; 2023 Jun; 226():165-172. PubMed ID: 37182388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [How to use AT concentrate or recombinant thrombomodulin for the patients with sepsis analyzed by laboratory markers].
    Eguchi Y; Yoshida T; Okabe H
    Rinsho Byori; 2011 Feb; Suppl 147():213-5. PubMed ID: 21761775
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical Outcomes of Recombinant Human-soluble Thrombomodulin Treatment for Disseminated Intravascular Coagulation in Solid Tumors.
    Kashiwagi S; Asano Y; Takahashi K; Shibutani M; Amano R; Tomita S; Hirakawa K; Ohira M
    Anticancer Res; 2019 May; 39(5):2259-2264. PubMed ID: 31092417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of antithrombin and recombinant human thrombomodulin combination therapy in patients with severe sepsis and disseminated intravascular coagulation.
    Yasuda N; Goto K; Ohchi Y; Abe T; Koga H; Kitano T
    J Crit Care; 2016 Dec; 36():29-34. PubMed ID: 27546744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombomodulin in disseminated intravascular coagulation and other critical conditions-a multi-faceted anticoagulant protein with therapeutic potential.
    Ito T; Thachil J; Asakura H; Levy JH; Iba T
    Crit Care; 2019 Aug; 23(1):280. PubMed ID: 31416465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of recombinant human soluble thrombomodulin in severe postpartum hemorrhage with disseminated intravascular coagulation.
    Sugawara J; Suenaga K; Hoshiai T; Sato T; Nishigori H; Nagase S; Yaegashi N
    Clin Appl Thromb Hemost; 2013 Sep; 19(5):557-61. PubMed ID: 22496090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A case of miliary tuberculosis complicated by disseminated intravascular coagulation and acute respiratory distress syndrome successfully treated with recombinant human soluble thrombomodulin].
    Shiraishi S; Futami S; Kurahara Y; Tsuyuguchi K; Hayashi S; Suzuki K
    Kekkaku; 2012 Dec; 87(12):771-6. PubMed ID: 23350518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.